ReAlta recently presented to an audience of doctors, pharmacists, residents and medical students at the Grand Rounds meeting of Children’s Hospital of the King’s Daughters (CHKD). During the meeting, ReAlta’s Program Director for Hypoxic Ischemic Encephalopathy (HIE), Lori Upham, presented an overview of ReAlta’s Health Economics and Outcomes Research plan for RLS-0071 as a therapy to treat HIE.
Betsy Pilon, Director of Hope For HIE, joined Lori in the presentation. Hope for HIE is the leading patient advocacy organization for families experiencing HIE with over 7000 members worldwide. Betsy presented an example of the HIE patient’s journey, including anecdotes about her son who was born with HIE. Hope for HIE families and ReAlta are collaborating on the development of a unique Quality of Life survey tool that will be integrated into ReAlta’s HIE study.
HIE is a rare and complex disease with long term effects for children and their families. To make a new treatment accessible requires enormous involvement by treating physicians as well as the public and private payors to make it available and affordable for all patients that need it. As such, ReAlta is working diligently to advance RLS-0071 as a transformational therapy. ReAlta plans to initiate a Phase 2 study with RLS-0071 as a treatment for HIE in 2023.
More information about Hope for HIE can be found at this link.